|1.||Webb, David J: 12 articles (03/2015 - 08/2002)|
|2.||Edvinsson, Lars: 10 articles (02/2015 - 05/2003)|
|3.||Barton, Matthias: 10 articles (11/2014 - 06/2003)|
|4.||Clozel, Martine: 9 articles (11/2015 - 01/2002)|
|5.||Frey, Aline: 8 articles (01/2013 - 10/2002)|
|6.||Dai, Yin: 8 articles (05/2010 - 09/2006)|
|7.||Kohan, Donald E: 7 articles (07/2015 - 03/2010)|
|8.||Goddard, Jane: 7 articles (03/2015 - 03/2004)|
|9.||Dhaun, Neeraj: 7 articles (03/2015 - 12/2005)|
|10.||Dai, De-Zai: 7 articles (05/2010 - 11/2006)|
|1.||Hypertension (High Blood Pressure)
01/01/2007 - "Selective blockade of endothelin receptors ET(A) is superior to non-selective ET(A)/ET(B) blockade in attenuating of hypertension and also morphology. "
03/01/2010 - "In preclinical studies, endothelin receptor antagonists were effective in treating hypertension (particularly with endothelial dysfunction) and CKD. "
01/01/2005 - "Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?"
04/01/2015 - "Finally, clinical trials indicate that antagonists of endothelin receptors hold great promise in treating resistant hypertension and proteinuric renal disease. "
01/29/2002 - "Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension."
|2.||Pulmonary Hypertension (Ayerza Syndrome)
10/01/2012 - "Treatment either with an antibody against TGF-β or with endothelin receptor blockade are equally effective in experimental pulmonary hypertension. "
02/01/2006 - "Endothelin receptor antagonists have been shown to be effective for long-term management of pulmonary hypertension. "
04/01/1995 - "This study investigated the pharmacologic effect of endothelin receptor antagonists on cardiopulmonary hemodynamic variables in a beagle model of pulmonary hypertension. "
11/24/2014 - "The 6-min walking distance is often used for assessing the exercise capacity under the treatment with an endothelin receptor antagonist (ERA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). "
11/24/2014 - "Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2."
01/01/2013 - "Endothelin receptor antagonists and scleroderma related digital ulcers."
01/01/2011 - "The purpose of this paper is to summarize the published studies and case reports evaluating the efficacy of endothelin receptor antagonists in the treatment of Raynaud's phenomenon and digital ulcers associated with systemic sclerosis."
11/24/2014 - "Endothelin receptor antagonists (ETRAs) are approved for the treatment of pulmonary hypertension and scleroderma-related digital ulcers. "
01/01/2011 - "Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis."
12/01/2004 - "Treatment with the endothelin receptor antagonist bosentan may be effective in preventing new digital ulcers and improving hand function in patients with SSc."
09/16/2014 - "In preclinical studies, endothelin receptor A (ETA) antagonists (ETAi) attenuated the progression of heart failure (HF). "
06/01/2006 - "Trials of endothelin receptor antagonists in heart failure have been completed with mixed results so far. "
10/01/2002 - "The results from the ENABLE study have, however, thrown further doubt on the potential benefits of non-specific endothelin receptor blockade in heart failure."
07/01/1998 - "Studies with endothelin-receptor antagonists in animals and humans with heart failure show promising short- and long-term results. "
03/01/2011 - "The rise and fall of endothelin receptor antagonists in congestive heart failure."
|5.||Systemic Scleroderma (Systemic Sclerosis)
06/01/2009 - "Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis."
05/01/2015 - "It is generally accepted that blockade of endothelin receptors has potentially beneficial effects on vasculopathy associated with systemic sclerosis (SSc). "
01/01/2013 - "Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis."
01/01/2012 - "Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients."
02/01/2011 - "Endothelin receptor antagonists as disease modifiers in systemic sclerosis."
|3.||Endothelin-1 (Endothelin 1)
|4.||Idiopathic pulmonary hypertension
|9.||N- (5- (4- bromophenyl)- 6- (2- (5- bromopyrimidin- 2- yloxy)ethoxy)pyrimidin- 4- yl)- N'- propylaminosulfonamide
|2.||Heart Transplantation (Grafting, Heart)
|3.||Molecular Targeted Therapy
|5.||Drug Therapy (Chemotherapy)